Jacobs Levy Equity Management Inc. Buys 39,698 Shares of CryoPort, Inc. $CYRX

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in CryoPort by 54%, acquiring an additional 39,698 shares, bringing its total holdings to 113,235 shares valued at approximately $688,000.
• A significant number of other institutional investors have also increased their stakes in CryoPort, with 92.90% of the stock currently owned by institutional investors.
• In recent transactions, insiders such as Director Robert J. Hariri and CEO Jerrell Shelton sold significant shares, resulting in a total of 449,413 shares being sold by insiders in the last ninety days.

Jacobs Levy Equity Management Inc. lifted its stake in CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 54.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 113,235 shares of the company's stock after acquiring an additional 39,698 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.23% of CryoPort worth $688,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in CYRX. Millennium Management LLC grew its stake in shares of CryoPort by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after acquiring an additional 409,353 shares during the period. Silvercrest Asset Management Group LLC grew its stake in shares of CryoPort by 77.0% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock worth $5,780,000 after acquiring an additional 323,216 shares during the period. Readystate Asset Management LP grew its stake in shares of CryoPort by 91.6% in the first quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock worth $3,042,000 after acquiring an additional 239,153 shares during the period. AQR Capital Management LLC grew its stake in shares of CryoPort by 285.5% in the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company's stock worth $1,597,000 after acquiring an additional 194,482 shares during the period. Finally, Trexquant Investment LP grew its position in CryoPort by 57.7% during the first quarter. Trexquant Investment LP now owns 377,127 shares of the company's stock valued at $2,293,000 after buying an additional 137,989 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Insider Activity at CryoPort

In other news, Director Robert J. Hariri sold 25,000 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $9.71, for a total value of $242,750.00. Following the transaction, the director owned 51,275 shares of the company's stock, valued at approximately $497,880.25. The trade was a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the completion of the transaction, the chief executive officer directly owned 912,419 shares in the company, valued at $6,213,573.39. This trade represents a 14.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 449,413 shares of company stock worth $3,160,008 over the last ninety days. 10.00% of the stock is owned by corporate insiders.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $8.64 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $10.46. The company has a market capitalization of $432.60 million, a P/E ratio of 6.50 and a beta of 1.62. The firm's 50 day simple moving average is $8.23 and its two-hundred day simple moving average is $6.90.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The firm had revenue of $45.45 million for the quarter, compared to analysts' expectations of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CYRX. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. BTIG Research cut their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Stephens began coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price for the company. Leerink Partners upgraded shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Wednesday, August 6th. Finally, KeyCorp upgraded shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price for the company in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, CryoPort currently has a consensus rating of "Buy" and a consensus target price of $12.00.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.